Accuracy of the Dexcom G7 Continuous Glucose Monitoring Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA-2 Study).

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes technology & therapeutics Pub Date : 2025-02-05 DOI:10.1089/dia.2024.0575
Parizad Avari, Reshaba Pushparatnam, Lala Leelarathna, Tricia Tan, Andrew H Frankel, Nick Oliver, Monika Reddy
{"title":"Accuracy of the Dexcom G7 Continuous Glucose Monitoring Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA-2 Study).","authors":"Parizad Avari, Reshaba Pushparatnam, Lala Leelarathna, Tricia Tan, Andrew H Frankel, Nick Oliver, Monika Reddy","doi":"10.1089/dia.2024.0575","DOIUrl":null,"url":null,"abstract":"<p><p>The accuracy of the latest generation Dexcom G7 sensors in individuals with diabetes undergoing hemodialysis has not previously been investigated. Participants with diabetes undergoing hemodialysis were recruited, with paired sensor glucose from Dexcom G7 recorded with plasma glucose analyzed in the laboratory, as well as the Freestyle Precision Pro glucometer and EKF Biosen C-Line analyzer. Ten adults (median age 64.0 [58.0-74.5] years) were recruited. Overall percentage (%) mean and median absolute relative differences were 10.4% and 8.5% for matched laboratory pairs, respectively (<i>n</i> = 720). Diabetes Technology Society error grid analysis showed 99.7%, 100%, and 99.9% of pairs within zones A and B for lab, glucometer, and EKF methods, respectively. This, the first Dexcom G7 accuracy study conducted in people on hemodialysis, demonstrates accuracy and safety when compared with lab reference readings. These data support the accessibility of continuous glucose monitoring (CGM) and hybrid closed-loop systems for people with diabetes on hemodialysis.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2024.0575","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The accuracy of the latest generation Dexcom G7 sensors in individuals with diabetes undergoing hemodialysis has not previously been investigated. Participants with diabetes undergoing hemodialysis were recruited, with paired sensor glucose from Dexcom G7 recorded with plasma glucose analyzed in the laboratory, as well as the Freestyle Precision Pro glucometer and EKF Biosen C-Line analyzer. Ten adults (median age 64.0 [58.0-74.5] years) were recruited. Overall percentage (%) mean and median absolute relative differences were 10.4% and 8.5% for matched laboratory pairs, respectively (n = 720). Diabetes Technology Society error grid analysis showed 99.7%, 100%, and 99.9% of pairs within zones A and B for lab, glucometer, and EKF methods, respectively. This, the first Dexcom G7 accuracy study conducted in people on hemodialysis, demonstrates accuracy and safety when compared with lab reference readings. These data support the accessibility of continuous glucose monitoring (CGM) and hybrid closed-loop systems for people with diabetes on hemodialysis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Dexcom G7连续血糖监测传感器在糖尿病血液透析患者中的准确性(ALPHA-2研究)
最新一代Dexcom G7传感器在接受血液透析的糖尿病患者中的准确性以前没有研究过。招募接受血液透析的糖尿病患者,使用Dexcom G7的配对血糖传感器记录血糖,在实验室分析血浆血糖,以及Freestyle Precision Pro血糖仪和EKF Biosen C-Line分析仪。纳入10名成人(中位年龄64.0[58.0-74.5]岁)。配对实验室对的总体百分比(%)平均和中位数绝对相对差异分别为10.4%和8.5% (n = 720)。糖尿病技术协会误差网格分析显示,实验室、血糖仪和EKF方法在A区和B区分别有99.7%、100%和99.9%的对。这是Dexcom G7首次在血液透析患者中进行的准确性研究,与实验室参考读数相比,证明了准确性和安全性。这些数据支持持续血糖监测(CGM)和混合闭环系统对血液透析糖尿病患者的可及性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
期刊最新文献
The Association of Time-in-Range and Time-in-Tight-Range with Retinopathy Progression in the Virtual Diabetes Control and Complications Trial Continuous Glucose Monitoring Dataset. A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes. FRONTIER-FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database-Evidence from Real-World Practice: Patients Using Intensive Insulin. Omnipod5 Real-World Data from the First Pediatric Users' Universal Coverage Under the UK National Health Service. Correlation Between A1c and Continuous Glucose Monitor Time in Range in a Cohort of Pediatric Patients with Type 1 Diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1